Kathleen Poston, MD
Clinical Neurophysiology · Stanford, CANPI 1114053808
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,588 of the $17,838 with a category attached, or 87.4%. Eli Lilly accounts for 96.2% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $17,154, more than ten times the $175 reported in 2019.
Across 15 payments — averaging $1189.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$17K
- Medtronic$439
- Insightec,inc$149
- Takeda Pharmaceuticals U.S.A., Inc.$96
Across 14 payments — averaging $31,405 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Corporation$371K
- Sanofi$69K
What the payments were for
- Consulting fees$15,58887%
- Travel & lodging$1,2647%
- Food & beverage$9866%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 10 | $17,154 |
| Medtronic(2 entities) | 3 | $439 |
| Insightec,inc | 1 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $96 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$300
- Exablate$149
- PERCEPT PC BRAINSENSE$139
How this compares
$17,838 in reported general payments places this provider in the 80th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 18 | $117,553 |
| RytaryCarbidopa/Levodopa | 16 | $39,911 |
| Droxidopa | 13 | $25,165 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 98 | $4,364 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 60 | $3,539 |
| AmantadineAmantadine Hcl | 16 | $1,207 |
| Mirtazapine | 44 | $956 |
| Quetiapine Fumarate | 19 | $927 |
| Clonazepam | 61 | $753 |
| Memantine Hcl | 15 | $597 |
| Clomipramine Hcl | 12 | $428 |
| Donepezil Hcl | 21 | $417 |
| Levetiracetam | 12 | $117 |
| Lamotrigine | 20 | $68 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in Stanford
- Christopher LockStanford$159K
- Srikanth MuppidiStanford$150K
- Mitchell MiglisStanford$51K
- Safwan JaradehStanford$34K
- Margaret FerrisStanford$18K
- Helen Bronte-StewartStanford$7K
- Jaime LopezStanford$1K
- Sungho ChoStanford$1K
- Felix ChangStanford$974
- Laurice YangStanford$924
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.